HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients

Journal of Immunology

Volumn 161, Issue 12, 1998, Pages 6970-6976

  Reynolds, Sandra R ^a   Celis, Esteban ^b,c   Sette, Alessandro ^c   Oratz, Ruth ^d   Shapiro, Richard L ^d   Johnston, Dean ^a   Fotino, Marilena ^e   Bystryn, Jean Claude ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Epimmune   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e ROGOSIN INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN; MELANOCORTIN RECEPTOR; MONOPHENOL MONOOXYGENASE; RECOMBINANT GAMMA INTERFERON;

ADULT; ARTICLE; BINDING AFFINITY; CANCER RISK; CLINICAL ARTICLE; EFFECTOR CELL; FEMALE; GENETIC HETEROGENEITY; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; MELANOMA; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SENSITIZATION;

ALLELES; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; TREATMENT OUTCOME;

EID: 0032534598     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Muul, L. M., P. J. Spiess, R. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989.
2. Itoh, K., C. D. Platsoucan, and C. M. Balch. 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168:1419.
3. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boël, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
4. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257.
5. Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
6. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Frasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
7. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
8. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, C. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
9. Wölfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K-H. Meyer zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
10. Cox. A., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingloff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716.
11. Jäeger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162.
12. Wang, R. F., E. Appella, Y. Kawakami, X. Kang, and S. A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207.
13. Salazar-Onfray, F., T. Nakazawa, V. Chhajlani M. Petersson, K. Karre, G. Masucci, E. Celis, A. Sette, S. Southwood, E. Appella, and R. Kiessling. 1997. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57:4348.
14. Reynolds, S. R., R. Oratz, R. L. Shapiro, M. Fotino, P. Hao, S. Vukmanović, and J.-C. Bystryn. 1997. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int. J. Cancer 72:972.
15. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
16. Coulie, P. G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J-P. Szikora, J-C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
17. Mountjoy, K. G., L. S. Robbins, M. T. Mortrud, and R. D. Cone. 1992. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248.
18. Cassady, J. L., and R. A. Sturm. 1994. Sequence of the human dopachrome tautomerase-encoding TRP-2 cDNA. Gene 143:295.
19. Yokoyama, K., K. Yasumoto, H. Suzuki, and S. Shibahara. 1994. Cloning of the human DOPAchrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression. J. Biol. Chem. 269:27080.
20. Olerup, O., and H. Zetterquist. 1992. HLA DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225.
21. Bystryn, J-C., S. Jacobsen, M. N. Harris, D. Roses, J. L. Speyer, and M. Levin. 1986. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J. Biol. Response Mod. 5:221.
22. Bystryn, J-C., R. L. Shapiro, and R. Oratz. 1995. Partially purified tumor antigens. In Biologic Therapy of Cancer, 2nd ed. V. T. DeVita, S. Hellman, and S. A. Rosenberg eds. Lippincott, Philadelphia, p. 668.
23. Bystryn, J.-C., M. Henn, J. Li, and S. Shroba. 1992. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 52:5948.
24. Gershman, N., D. Johnston, and J.-C. Bystryn. 1994. Potentiation of B16 melanoma vaccine immunogenicity by IL-2 liposomes. Vaccine Res. 3:82.
25. Sette, A., J. Sidney, M. F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H. M. Grey, and R. T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31:813.
26. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. del Guercio, S. Southwood, R. T. Kubo, R. W. Chesnut, H. M. Grey, and F. V. Chisari. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
27. Bednarek, M. A., S. Y. Maureen, M. D. Gammon, G. Porter. S. Tamhankar, A. R. Williamson, and H. J. Zweerink. 1991. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J. Immunol. 147:4047.
28. Blum-Tirouvanziam, U. C. Servis, A. Habluetzel, D. Valmori, Y. Men, F. Esposito, L. Del Nero, N. Holmes, N. Fasel, and G. Corradin. 1995. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 154:3922.
29. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
30. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796.
31. Kang, X., Y. Kawakami, M. El-Gamil, R. Wang, K. Sakaguchi, J. R. Yannelli, E. Appella, S. A. Rosenberg, and P. F. Robbins. 1995. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. 155:1343.
32. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wölfel, D. Lienard, V. Brichard, A. van Pel, F. Jotereau, and J.-C. Cerottini. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.